The guinea pig model of genital herpes simplex virus infection has proven useful in the evaluation of antiviral drugs. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced positive 12 month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. A two‐way interaction between mood and message framing on the dependent variable(s) was hypothesized such that persons in a sad mood will be more persuaded (as evidenced by heightened threat, efficacy, attitude, intention and behavior) by a negatively framed message given its mood congruent qualities. The “moving wall” represents the time period between the last issue available in JSTOR and the most recently published issue of a journal. When treatment was begun after ultraviolet exposure, neither topical nor intraperitoneal acyclovir were effective in reducing the incidence or severity of induced recurrent disease. Subjects were randomized to one of six dosing groups of either 30 µg or 60 µg per protein paired with one of three adjuvant doses (25 µg, 50 µg, or 75 µg). In the main, frame and mood elicited separate effects.
For example, if the current year is 2008 and a journal has a 5 year moving wall, articles from the year 2002 are available. Terms Related to the Moving Wall Fixed walls: Journals with no new volumes being added to the archive. This 28-day observation period was repeated immediately after the completion of dosing and at six and, twelve months following dosing. Complete: Journals that are no longer published or that have been combined with another title.